Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Etaracizumab, an antibody targeting ITGAVB3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Conatumumab, an antibody targeting TNFRSF10B.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cixutumumab, an antibody targeting IGF-1R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sifalimumab, an antibody targeting IFNA1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rontalizumab, an antibody targeting IFNA1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rilotumumab, an antibody targeting HGF.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Intetumumab, an antibody targeting ITGAVB3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dalotuzumab, an antibody targeting IGF-1R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tregalizumab, an antibody targeting CD4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ponezumab, an antibody targeting Amyloid-beta.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Oxelumab, an antibody targeting OX40L.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lorvotuzumab, an antibody targeting NCAM1.